Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
25 Apr 24
6-K
Report of Foreign Private Issuer
16 Apr 24
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
2 Feb 24
F-3
Shelf registration (foreign)
30 Jan 24
6-K
Report of Foreign Private Issuer
18 Jan 24
D
$1.69 mm in equity / options / securities to be acquired, sold $1.69 mm, 4 investors
12 Jan 24
6-K
Report of Foreign Private Issuer
9 Jan 24
6-K
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
4 Jan 24
424B3
Prospectus supplement
2 Jan 24
424B3
Prospectus supplement
2 Jan 24
6-K
Report of Foreign Private Issuer
2 Jan 24
6-K
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
2 Jan 24
424B3
Prospectus supplement
2 Jan 24
EFFECT
Notice of effectiveness
27 Dec 23
CORRESP
Correspondence with SEC
26 Dec 23
F-1/A
Registration statement (foreign) (amended)
22 Dec 23
6-K
Report of Foreign Private Issuer
14 Dec 23
6-K
Report of Foreign Private Issuer
20 Nov 23
6-K
Report of Foreign Private Issuer
13 Nov 23
6-K
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
7 Nov 23
6-K
Report of Foreign Private Issuer
3 Nov 23
6-K
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
2 Nov 23
F-1
Registration statement (foreign)
30 Oct 23
D
$1.33 mm in equity / options / securities to be acquired, sold $1.33 mm, 1 investor
3 Oct 23
6-K
Report of Foreign Private Issuer
22 Sep 23
6-K
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
20 Sep 23
6-K
Report of Foreign Private Issuer
19 Sep 23
424B5
Prospectus supplement for primary offering
19 Sep 23
6-K
Report of Foreign Private Issuer
11 Sep 23
424B3
Prospectus supplement
7 Sep 23
6-K
Report of Foreign Private Issuer
6 Sep 23
6-K
Report of Foreign Private Issuer
6 Sep 23
424B2
Prospectus for primary offering
28 Aug 23
EFFECT
Notice of effectiveness
28 Aug 23
6-K
Report of Foreign Private Issuer
24 Aug 23
6-K
Report of Foreign Private Issuer
23 Aug 23
CORRESP
Correspondence with SEC
23 Aug 23
UPLOAD
Letter from SEC
22 Aug 23
Latest ownership filings
SC 13D
STONE DANIEL E.
12 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
STONE DANIEL E.
24 Jan 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
STONE DANIEL E.
6 Feb 23
3/A
YAEL MARGOLIN
23 Jan 23
3/A
Morris C Laster
23 Jan 23
3/A
George Lowell
23 Jan 23
3/A
Avner Rotman
23 Jan 23
3
Samuel J Moed
5 Jan 23
SC 13G
SABBY MANAGEMENT, LLC
4 Jan 23
3
Jay Green
3 Jan 23
3
YAEL MARGOLIN
3 Jan 23
3
Uri Ben-Or
3 Jan 23
3
Tamar Ben-Yedidia
3 Jan 23
3
Morris C Laster
3 Jan 23
3
MARK GERMAIN
3 Jan 23
3
George Lowell
3 Jan 23
3
Avner Rotman
3 Jan 23
3
Amir Reichman
3 Jan 23
3
Adi Raviv
3 Jan 23
3
Elad Mark
3 Jan 23
SC 13D/A
NACHT MARIUS
27 Dec 22
SC 13G
STONE DANIEL E.
6 Oct 22
SC 13D/A
NACHT MARIUS
11 Jan 22
SC 13D/A
NACHT MARIUS
9 Feb 21
SC 13G/A
BiondVax Pharmaceuticals Ltd.
24 Jan 20
SC 13D/A
BiondVax Pharmaceuticals Ltd.
12 Nov 19
SC 13G/A
BiondVax Pharmaceuticals Ltd.
28 Jan 19
SC 13G/A
BiondVax Pharmaceuticals Ltd.
2 Feb 18
SC 13D/A
BiondVax Pharmaceuticals Ltd.
27 Sep 17
SC 13G
BiondVax Pharmaceuticals Ltd.
26 Sep 17
SC 13G
BiondVax Pharmaceuticals Ltd.
22 Sep 17
SC 13D
BiondVax Pharmaceuticals Ltd.
16 Feb 17
SC 13G
BiondVax Pharmaceuticals Ltd.
16 Feb 16